TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33539749
Drug: Short‐course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short‐course radiotherapy followed by chemotherapy before total mesorectal excision (TME)
Study: 33539749
Drug: Preoperative chemoradiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy
Study: 35286849
Drug: Placebo+Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+Therapy
Study: 36052360
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 10 mg kg−1
Study: 35862389
Drug: 200% recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200% recommended dose of fertilizer (RDF) with planting in the first week of October
Study: 35862389
Drug: 200% recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200% recommended dose of fertilizer (RDF) with planting in the second week of October
Study: 35862389
Drug: 150% recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150% recommended dose of fertilizer (RDF) with planting in the first week of October
Study: 35862389
Drug: 100% recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% recommended dose of fertilizer (RDF) with planting in the first week of October
Study: 35862389
Drug: 150% recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150% recommended dose of fertilizer (RDF) with planting in the first fortnight of October
Study: 35862389
Drug: 150% recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150% recommended dose of fertilizer (RDF) with planting in the second week of October
Study: 35862389
Drug: 100% recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% recommended dose of fertilizer (RDF) with planting in the first and second week of October
Study: 34989804
Drug: Bevacizumab (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (1.25 mg/0.05 mL)
Study: 35876254
Drug: Treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments
Study: 34644619
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment/non-exercise)
Study: 33573486
Drug: NPWT+ (Negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPWT+ (Negative Pressure Wound Therapy Plus)
Study: 33573486
Drug: NPWT (Negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPWT (Negative Pressure Wound Therapy)
Study: 33058694
Drug: CRTT‐L‐Cantonese
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRTT‐L‐Cantonese
Study: 33058694
Drug: CRTT‐R‐WF‐Cantonese and
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRTT‐R‐WF‐Cantonese and CRTT‐L‐Cantonese
Study: 33206786
Drug: Whole purple
Normalized name: Purple coneflower whole
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole purple grape juice (400 ml; 200 ml before and 200 ml after training)
Study: 33206786
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (water; 400 ml; 200 ml before and 200 ml after training)
Study: 32520900
Drug: Transdermal 17β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β estradiol (tE2) 50μg/d
Study: 32520900
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (oCEE) 0.45mg/d
Study: 32613644
Drug: Online Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Cognitive Behavioural Therapy (CBT)
Study: 32118739
Drug: Fu's subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu's subcutaneous needling (FSN) therapy, 12 sessions over 3 weeks
Study: 32118739
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy at specified points using acupuncture needles
Study: 32118739
Drug: FSN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSN therapy
Study: 35765921
Drug: 2-g intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g intravenous TXA
Study: 35765921
Drug: 4-g intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-g intravenous TXA
Study: 33583027
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of dexamethasone (12 mg intravenously daily for up to 10 days)
Study: 33583027
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of dexamethasone (6 mg intravenously daily for up to 10 days)
Study: 35477419
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity guideline only (control group G)
Study: 32416983
Drug: Group 2T10I
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2T10I (screws tightened twice with a 10-minute interval)
Study: 32416983
Drug: Group 2T0I
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2T0I (screws tightened twice with no interval)
Study: 34706691
Drug: Psychodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic therapy (PDT)
Study: 36271193
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment intensity (average 3.7 ± 2.6 equivalent medications at usual dosages)
Study: 32564693
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system inhibitors
Study: 36082154
Drug: Handgrip-strengthening exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handgrip-strengthening exercises (HGSE) added to conventional therapy
Study: 36082154
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (ultrasound therapy, ice, and stretching exercises)
Study: 32681996
Drug: Auto-cross-linked hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-cross-linked hyaluronic acid gel after surgery
Study: 34351452
Drug: Volumetric modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumetric modulated arc therapy (VMAT) with two small tangential subarcs
Study: 32227754
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy (initial angiography and revascularization plus guideline‐based medical therapy)
Study: 32227754
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy (guideline‐based medical therapy alone)
Study: 35667065
Drug: Molnupiravir, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir, 800 mg, every 12 hours for 5 days
Study: 34914219
Drug: Pressing acupuncture
Normalized name: LEMON OIL, COLD PRESSED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressing acupuncture therapy (PAT) combined with auricular pressure beans
Study: 34914219
Drug: Auricular pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular pressure beans combined with drug therapy
Study: 33400434
Drug: r-TMS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-TMS (5 Hz, 20-minute daily session, 5 days per week, for a total of 10 sessions)
Study: 35379222
Drug: Pain neuroscience
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain neuroscience education (PNE) and exercise intervention, 6 weekly sessions plus one review session after 1 month.
Study: 35379222
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received treatment as usual (TAU).
Study: 32381795
Drug: Bubble Breath
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bubble Breath Play Therapy (BBPT)
Study: 36286651
Drug: Bulevirtide monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulevirtide monotherapy for 24 weeks (MYR202 study)
Study: 36286651
Drug: Bulevirtide monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulevirtide monotherapy and combination with PEG‐IFN for 48 weeks (MYR203 study)
Study: 35395819
Drug: Core stability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core stability training (15 min) + conventional treatment (40 min/day, 5 times/week for 8 weeks)
Study: 35395819
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (40 min/day, 5 times/week for 8 weeks)
Study: 33639967
Drug: Tomato powder
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato powder (30 mg lycopene, 5.38 mg beta-carotene, 22.32 mg phytoene, 9.84 mg phytofluene)
Study: 33639967
Drug: Lycopene supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplement (30 mg lycopene)
Study: 35648053
Drug: Interactive video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive video games (IVGs) + traditional neurodevelopment treatment (TNT)
Study: 35648053
Drug: Walking training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking training + traditional neurodevelopment treatment (TNT)
Study: 34612724
Drug: Blonanserin tablet
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin tablet (4 to 24 mg/day, orally administered twice daily for 52 weeks)
Study: 34612724
Drug: Blonanserin tablet
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin tablet (DB-blonanserin group)
Study: 34612724
Drug: Blonanserin tablet
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin tablet
Study: 33302270
Drug: Pomegranate Seed
Normalized name: pomegranate seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate Seed Powder (PSP) 5 g, twice daily for 8 weeks
Study: 32416538
Drug: Point-of-care (POC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care (POC) HCV antibody testing by peer outreach workers
Study: 33710587
Drug: Topical 17-β-estradiol-3-phosphate
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 17-β-estradiol-3-phosphate eye drops (0.05% twice daily)
Study: 33710587
Drug: Topical 17-β-estradiol-3-phosphate
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 17-β-estradiol-3-phosphate eye drops (0.1% morning, vehicle in the evening)
Study: 33710587
Drug: Topical 17-β-estradiol-3-phosphate
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 17-β-estradiol-3-phosphate eye drops (0.1% twice daily)
Study: 33710587
Drug: Topical 17-β-estradiol-3-phosphate
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 17-β-estradiol-3-phosphate eye drops and Vehicle
Study: 35101086
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy combined with fluticasone propionate nasal spray
Study: 35101086
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray alone
Study: 33126335
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 800 mg/day for 2 weeks, followed by 400 mg/day for 8 weeks and 200 mg/day for 42 weeks
Study: 33126335
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 400 mg/day for 52 weeks
Study: 33126335
Drug: No antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifungal treatment
Study: 35603772
Drug: Telehealth mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth mindfulness-based cognitive therapy (MBCT-PD)
Study: 35835612
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (IV)
Study: 34579146
Drug: Nut consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nut consumption (30 g/d of walnuts, almonds, and hazelnuts)
Study: 33828613
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) sampling
Study: 34797440
Drug: Small blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small blood loss (SBL) < 200 ml (n = 404)
Study: 34797440
Drug: Medium blood
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium blood loss (MBL) 200 ml ≤ IBL < 400 ml (n = 393)
Study: 34797440
Drug: Large blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large blood loss (LBL) IBL ≥ 400 ml (n = 406)
Study: 35241003
Drug: Adjunctive istradefylline
Normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive istradefylline (20 mg/day, increasing to 40 mg/day)
Study: 35241003
Drug: Control (levodopa-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (levodopa-containing medications only)
Study: 34460155
Drug: L-DOPA therapy
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA therapy at the peak
Study: 34460155
Drug: L-DOPA therapy
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA therapy at the outcome
Study: 32232692
Drug: Ninjin'yoeito (NYT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ninjin'yoeito (NYT) 9.0 g/day
Study: 35863786
Drug: Ropivacaine (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (3.75 mg/mL)
Study: 33405340
Drug: Proglumetacin (tested
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumetacin (tested twice independently, with AC50 of 8.9 µM and 12.5 µM)
Study: 32407216
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2, day 1) plus cisplatin (75 mg/m2, day 1)
Study: 32407216
Drug: Vinorelbine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25 mg/m2, days 1 and 8) plus cisplatin (80 mg/m2, day 1)
Study: 33983512
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg HBB intravenously
Study: 35889746
Drug: Low-dose quadruple
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose quadruple therapy with bismuth (two capsules of Pylera® plus 250 mg each of tetracycline and metronidazole)
Study: 35889746
Drug: Low-dose quadruple
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose quadruple therapy with Lactobacillus reuteri (Gastrus®), one tablet twice-a-day for 27 days
Study: 33159999
Drug: Neuraminidase inhibitors
Normalized name: Neuraminidase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuraminidase inhibitors (NAIs) for influenza B treatment; specific dosage and duration not mentioned.
Study: 33159999
Drug: Polymerase inhibitor
Normalized name: RNA polymerase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymerase inhibitor baloxavir in high-risk influenza B patients; specific dosage and duration not mentioned.
Study: 32164439
Drug: Lung cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer screening (LCS) by low-dose computed tomography (LDCT)
Study: 36385638
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for anxiety
Study: 32679568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal daily physical activity)
Study: 34162777
Drug: Pharmaceutical consultation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical consultation targeting outpatients by a pharmacist
Study: 34162777
Drug: Nonintervention (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonintervention (no pharmaceutical consultation)
Study: 34784108
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (0.5 g single oral PZA)
Study: 34784108
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (0.5 g single oral PZA)
Study: 34290666
Drug: High-concentration oxygen
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration oxygen treatment [FiO280 (8 L/min)] for 6 hours
Study: 34290666
Drug: Low-oxygen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-oxygen treatment [FiO230 (2 L/min)] for 6 hours
Study: 32555939
Drug: Esmolol (0.5‐mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5‐mg/kg bolus followed by infusion at 15 µg/kg/min)
Study: 32555939
Drug: Saline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (30 mL bolus and infusion)
Study: 34933721
Drug: Transplanted cartilage
Normalized name: SHARK CARTILAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplanted cartilage tissue and implants
Study: 34933721
Drug: Implants only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants only
Study: 34990776
Drug: Whole Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Breast Radiation Therapy (WBRT) with T-DM1
Study: 34990776
Drug: Whole Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Breast Radiation Therapy (WBRT) with TH
Study: 33012517
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml kg−1 caudal injection of 0.2% ropivacaine
Study: 33012517
Drug: Injection pauses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pauses during caudal block
Study: 32029439
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine
Study: 32029439
Drug: Conventional-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional-dose cytarabine
Study: 32029439
Drug: Two courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two courses of intermediate-dose cytarabine with daunorubicin or mitoxantrone
Study: 35654569
Drug: Risk perception
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risk perception of developing oral disease
Study: 36253765
Drug: Citrus peel
Normalized name: CITRUS AURANTIUM PEEL OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus peel extract (400 mg containing 0.1 mg of AUR and 3 mg of NAR)
Study: 34022138
Drug: Nasal High-Flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal High-Flow Oxygen (NHFS) (40% O2, 40 L/min, 37 °C)
Study: 34022138
Drug: Conventional Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Nasal Cannula (5 L/min)
Study: 33884929
Drug: Weekly pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly pain ratings
Study: 33884929
Drug: Daily pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pain ratings
Study: 33884929
Drug: Weekly ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly ratings compared to daily ratings
Study: 33884929
Drug: Weekly ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly ratings
Study: 38753374
Drug: Antidepressant monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant monotherapy
Study: 35613418
Drug: Topical ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ganciclovir 0.15% ophthalmic gel (1 drop 3 times daily, n = 6 cats)
Study: 35613418
Drug: Oral famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral famciclovir (90 mg/kg twice daily, n = 6)
Study: 35613418
Drug: Topical artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical artificial tear gel (1 drop 3 times daily, n = 4)
Study: 32768690
Drug: 3-item self-reported
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-item self-reported measure of adherence to medication
Study: 34010546
Drug: Concurrent Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Training (CT) with 15% velocity loss (VL15)
Study: 34010546
Drug: Concurrent Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Training (CT) with 45% velocity loss (VL45)
Study: 36331315
Drug: Inclisiran 284
Normalized name: INCLISIRAN 284MG/1.5ML INJ,SOLN,SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran 284 mg
Study: 35945594
Drug: Rosa foetida
Normalized name: Ballota foetida extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosa foetida extract capsules
Study: 32585581
Drug: Z5 (5
Normalized name: Zoledronic acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Z5 (5 mg/kg/day)
Study: 32585581
Drug: Z10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z10 (10 mg/kg/day)
Study: 33612438
Drug: Automated Self-Administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24-2016)
Study: 33612438
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA24-2016 recalls and DHQ-II
Study: 34258913
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg, every night for 4 weeks)